Construction of a Ferroptosis-Related Long Non-coding RNA Prognostic Signature and Competing Endogenous RNA Network in Lung Adenocarcinoma

Abstract

Ferroptosis-related genes play an important role in the progression of lung adenocarcinoma (LUAD). However, the potential function of ferroptosis-related lncRNAs in LUAD has not been fully elucidated. Thus, to explore the potential role of ferroptosis-related lncRNAs in LUAD, the transcriptome RNA-seq data and corresponding clinical data of LUAD were downloaded from the TCGA dataset. Pearson correlation was used to mine ferroptosis-related lncRNAs. Differential expression and univariate Cox analysis were performed to screen prognosis related lncRNAs. A ferroptosis-related lncRNA prognostic signature (FLPS), which included six ferroptosis-related lncRNAs, was constructed by the least absolute shrinkage and selection operator (LASSO) Cox regression. Patients were divided into a high risk-score group and low risk-score group by the median risk score. Receiver operating characteristic (ROC) curves, principal component analysis (PCA), and univariate and multivariate Cox regression were performed to confirm the validity of FLPS. Enrichment analysis showed that the biological processes, pathways and markers associated with malignant tumors were more common in high-risk subgroups. There were significant differences in immune microenvironment and immune cells between high- and low-risk groups. Then, a nomogram was constructed. We further investigated the relationship between six ferroptosis-related lncRNAs and tumor microenvironment and tumor stemness. A competing endogenous RNA (ceRNA) network was established based on the six ferroptosis-related lncRNAs. Finally, we detected the expression levels of ferroptosis-related lncRNAs in clinical samples through quantitative real-time polymerase chain reaction assay (qRT-PCR). In conclusion, we identified the prognostic ferroptosis-related lncRNAs in LUAD and constructed a prognostic signature which provided a new strategy for the evaluation and prediction of prognosis in LUAD.

A Novel Ferroptosis-Related lncRNAs Signature Predicts Clinical Prognosis and Is Associated With Immune Landscape in Pancreatic Cancer

“…Three ferroptosis-related lncRNAs (DUXAP8, LINC02609, and LUCAT1) ( Xing et al, 2021 ) were reported to significantly correlate with the overall survival and clinicopathological features of kidney renal clear cell carcinoma. In another study ( Fei et al, 2021 ), a ferroptosis-related lncRNA prognostic signature (FLPS), which included six ferroptosis-related lncRNAs, provided a new strategy for the prediction of prognosis in lung adenocarcinoma.…”

Necroptosis-related lncRNA in lung adenocarcinoma: A comprehensive analysis based on a prognosis model and a competing endogenous RNA network

“…Increasing evidence suggests that LUAD lncRNA plays an important role in prognosis and immunotherapeutic response. Several studies have developed lncRNA prognosis signatures, such as m6A-related ( Wang et al, 2021b ), ferroptosis-related ( Fei et al, 2021 ), pyroptosis-related ( Song et al, 2021 ), immune-related ( Qi et al, 2021 ), and metastasis-related lncRNA signatures ( Dou et al, 2021 ). However, NRLs are still being investigated, and their prognostic role in LUAD remains unclear.…”

Identification and validation of a novel ferroptosis-related 11-lncRNA prognostic signature related to immune infiltration and drug sensitivity in ccRCC

“…Li et al successfully constructed a novel ferroptosis-related lncRNAs signature, which may contribute to improve the prognosis prediction and immunotherapy response of non-small cell lung cancer (NSCLC) patients [20]. Fei et al identi ed the prognostic ferroptosis-related lncRNAs in lung adenocarcinoma (LUAD) and constructed a prognostic signature which provided a new strategy for the evaluation and prediction of prognosis in LUAD [21]. Xing et al identi ed three ferroptosis-related DELs (DUXAP8, LINC02609 and LUCAT1) which can be used as prognostic signatures to predict the outcome of patients with KIRC [22].…”